CODEXIS, INC.
About CODEXIS, INC.
Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $70.4M
- Net income
- -$44.0M
- Total assets
- $147.8M
- Market cap
- $232.7M
- Gross margin
- 86.7%
- Operating margin
- -59.3%
- Net margin
- -62.5%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $70.4M
- Cost of revenue
- $9.3M
- Gross profit
- $61.0M
- Operating expenses
- $102.8M
- Operating income
- -$41.7M
- Income tax
- $47.0K
- Net income
- -$44.0M
- EPS (basic)
- $-0.50
- EPS (diluted)
- $-0.50
Balance sheet
- Total assets
- $147.8M
- Current assets
- $96.8M
- Total liabilities
- $97.3M
- Current liabilities
- $25.3M
- Shareholders’ equity
- $50.5M
Cash flow
- Operating cash flow
- -$19.4M
- Investing cash flow
- $23.5M
- Financing cash flow
- $27.9M
- Net cash flow
- $32.1M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $232.7M
- EPS (diluted)
- $-0.5
- Shares outstanding
- 89.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Apr 22, 2010
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $44.0M in FY2025.
- Revenue grew 2% from FY2020 to FY2025.
- Gross margin of 86.7%, net margin -62.5%.
- Trading 22% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review CODEXIS, INC..
Write a review
News about CODEXIS, INC.
News & sentiment via Polygon.io
